Definium Therapeutics Stock Performance
| DFTX Stock | 16.90 0.65 4.00% |
On a scale of 0 to 100, Definium Therapeutics holds a performance score of 11. The firm shows a Beta (market volatility) of 0.17, which means not very significant fluctuations relative to the market. As returns on the market increase, Definium Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Definium Therapeutics is expected to be smaller as well. Please check Definium Therapeutics' downside variance, and the relationship between the total risk alpha and daily balance of power , to make a quick decision on whether Definium Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Definium Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent basic indicators, Definium Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 4 | Five Day Return (3.98) | Year To Date Return 23.9 | Ten Year Return 400 | All Time Return 400 |
1 | MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026 - Business Wire | 01/12/2026 |
2 | Deinium Therapeutics Is Up 11.5 percent After Psychedelic Rebrand And DT120 Roadmap Reveal Has The Bull Case Changed | 01/22/2026 |
3 | Insider Trading | 01/29/2026 |
4 | Is Adsetts Board Appointment And Breakthrough DT120 Status Altering The Investment Case For Definium Therapeutics | 02/05/2026 |
| Begin Period Cash Flow | 99.7 M | |
| Free Cash Flow | -79.1 M |
Definium Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,248 in Definium Therapeutics on November 11, 2025 and sell it today you would earn a total of 442.00 from holding Definium Therapeutics or generate 35.42% return on investment over 90 days. Definium Therapeutics is currently generating 0.5684% in daily expected returns and assumes 3.8134% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Definium, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Definium Therapeutics Target Price Odds to finish over Current Price
The tendency of Definium Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 16.90 | 90 days | 16.90 | about 5.86 |
Based on a normal probability distribution, the odds of Definium Therapeutics to move above the current price in 90 days from now is about 5.86 (This Definium Therapeutics probability density function shows the probability of Definium Stock to fall within a particular range of prices over 90 days) .
Definium Therapeutics Price Density |
| Price |
Predictive Modules for Definium Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Definium Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Definium Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Definium Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Definium Therapeutics is not an exception. The market had few large corrections towards the Definium Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Definium Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Definium Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.53 | |
β | Beta against Dow Jones | 0.17 | |
σ | Overall volatility | 2.10 | |
Ir | Information ratio | 0.12 |
Definium Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Definium Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Definium Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Definium Therapeutics appears to be risky and price may revert if volatility continues | |
| Definium Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Definium Therapeutics was previously known as Mind Medicine and was traded on NASDAQ Exchange under the symbol MNMD. | |
| Net Loss for the year was (108.68 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Definium Therapeutics generates negative cash flow from operations | |
| Latest headline from simplywall.st: Is Adsetts Board Appointment And Breakthrough DT120 Status Altering The Investment Case For Definium Therapeutics |
Definium Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Definium Stock often depends not only on the future outlook of the current and potential Definium Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Definium Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 704.6 M | |
| Cash And Short Term Investments | 273.7 M |
Definium Therapeutics Fundamentals Growth
Definium Stock prices reflect investors' perceptions of the future prospects and financial health of Definium Therapeutics, and Definium Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Definium Stock performance.
| EBITDA | (105.87 M) | ||||
| Net Income | (108.68 M) | ||||
| Total Debt | 21.85 M | ||||
| Cash Flow From Operations | (79.13 M) | ||||
| Total Asset | 302.15 M | ||||
| Retained Earnings | (398.88 M) | ||||
| Working Capital | 242.77 M | ||||
About Definium Therapeutics Performance
Evaluating Definium Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Definium Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Definium Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.45) | (0.48) | |
| Return On Assets | (0.41) | (0.43) | |
| Return On Equity | (0.52) | (0.54) |
Things to note about Definium Therapeutics performance evaluation
Checking the ongoing alerts about Definium Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Definium Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Definium Therapeutics appears to be risky and price may revert if volatility continues | |
| Definium Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Definium Therapeutics was previously known as Mind Medicine and was traded on NASDAQ Exchange under the symbol MNMD. | |
| Net Loss for the year was (108.68 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Definium Therapeutics generates negative cash flow from operations | |
| Latest headline from simplywall.st: Is Adsetts Board Appointment And Breakthrough DT120 Status Altering The Investment Case For Definium Therapeutics |
- Analyzing Definium Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Definium Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Definium Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Definium Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Definium Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Definium Therapeutics' stock. These opinions can provide insight into Definium Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Definium Stock Analysis
When running Definium Therapeutics' price analysis, check to measure Definium Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Definium Therapeutics is operating at the current time. Most of Definium Therapeutics' value examination focuses on studying past and present price action to predict the probability of Definium Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Definium Therapeutics' price. Additionally, you may evaluate how the addition of Definium Therapeutics to your portfolios can decrease your overall portfolio volatility.